Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2026-01-22 @ 1:38 AM
Study NCT ID:
NCT00911794
Status:
COMPLETED
Last Update Posted:
2009-06-02
First Post:
2009-05-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease
Sponsor:
Winthrop University Hospital
Organization:
Study Overview
Official Title:
Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.
Detailed Description:
Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: